DESIGN THERAPEUTICS INC (DSGN)
Health Care · biotechnology · NASDAQ
Design Therapeutics is a biopharmaceutical company pioneering GeneTAC small-molecule therapies to treat the root causes of serious genetic diseases.
What DESIGN THERAPEUTICS INC does
Design Therapeutics is a clinical-stage biopharmaceutical company focused on developing a proprietary class of small-molecule medicines called GeneTAC (Gene Targeted Chimera) molecules. These molecules are designed to regulate gene expression and treat serious genetic diseases by targeting underlying genetic causes rather than just symptoms. The company's platform aims to address various genetic disorders through the modulation of gene expression.
Themes: gene therapy, genetic diseases, small molecule therapeutics, biotech R&D
Fundamentals
- Price$14.99 as of 2026-08-21 close
- Market cap$938M as of 2026-08-21
- 1-year return+191.1% 2025-08-21 close $5.15 → 2026-08-21 close $14.99
- P/En/a negative earnings
- Net margin-3600.0% as of 2026-08-24
- ROE-34.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.65 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How DSGN compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How DESIGN THERAPEUTICS INC looks technically
DESIGN THERAPEUTICS INC (DSGN) is trading 33.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 238 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 33.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +33.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.44 | $13.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.21 | $11.21 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 11.45. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 238 trading days ago — a "golden cross", a bullish long-term signal | 238 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 27.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 59.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($12.62 to $16.12) — its "stochastic" reading is 68 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 67.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.25 | $17.25 |
|---|---|---|
| From the 52-week high | it is 13.1% below its 52-week high (its highest price of the past year) | -13.1% |
| Above the 52-week low | it is 220.3% above its 52-week low (its lowest price of the past year) | +220.3% |
| Below the 52-week high | it is 13.1% below its highest point of the past year | 13.1% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $43.00 (set on 2021-03-29) | $43.00 |
| Given back of the 52-week move | over the past year its closes ranged ($4.79 to $15.94), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.69 to $9.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 8.5% |
| From the all-time high | it is 65.1% below its all-time high | -65.1% |
| Nearest price level | it is trading 20.6% above a support level at $11.91 — a price it turned at twice since 2026-04-24, most recently on 2026-05-27. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -20.6% |
| All-time low | its lowest closing price on record is $1.94 (set on 2023-08-22) | $1.94 |
| Above the all-time low | it is 672.7% above its all-time low | +672.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7528 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7528 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.35 and $16.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.35 – $13.88 – $16.41 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (33.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Gap filled | a 10.5% gap up opened on 2026-07-27 has been "filled" 18 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 18 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.96% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 22.0 percentage points (the stock gained 24.3% while the market gained 2.3%) | +22.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 33.1 percentage points (the stock gained 36.1% while the market gained 3.1%) | +33.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 37.2 percentage points (the stock gained 48.3% while the market gained 11.1%) | +37.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 170.6 percentage points (the stock gained 191.1% while the market gained 20.5%) | +170.6% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.5% of the share price. | +8.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $12.30 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +21.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $14.62 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +2.6% |
Price levels it has turned at before
DSGN last closed at $14.99 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.91 | Support | 20.6% below the last close | turned there twice · 2026-04-24 to 2026-05-27 |
| $11.19 | Support | 25.4% below the last close | turned there twice · 2026-02-25 to 2026-03-16 |
| $10.14 | Support | 32.4% below the last close | turned there twice · 2025-12-22 to 2026-01-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $11.45.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $17.44 and $21.14 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $11.45.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market · Trading above the Ichimoku cloud · Most technical signals bullish | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$21.00 range $20.00 – $22.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DSGN
- Consensus EPS estimate-$0.3529 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the clinical stage and has a history of losses, with significant uncertainty regarding future profitability and the ability to successfully develop and commercialize its drug candidates.","Success depends heavily on the clinical and regulatory progress of its proprietary GeneTAC platform and individual drug candidates."]
What changed in the latest 10-Q
AI-assisted comparison of DSGN's 10-Q filed 2026-04-28 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added: 'In December 2025, the clinical hold was lifted and we received clearance from the FDA to initiate clinical studies for DT-216P2.' (filed 2026-04-28)
- Added: 'We anticipate providing an update from the RESTORE-FA trial on the effect of DT-216P2 on endogenous frataxin levels in the second half of 2026.' (filed 2026-04-28)
- Removed:
- Removed: 'In February 2022, the Investigational New Drug Application (IND) for our lead FA GeneTAC ® small molecule, DT-216, formulated as the prior DT-216 product candidate, was cleared by the U.S. Food and Drug Administration (FDA) to commence Phase 1 clinical trials. In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate.' (filed 2025-11-05)
- Removed: 'and we observed five cases of injection site thrombophlebitis in the Phase 1 MAD clinical trial' (filed 2025-11-05)
- Removed: 'to enable higher exposure and chronic administration for treatment of FA' replaced with 'to enable more sustained exposure for the treatment of FA' (filed 2026-04-28)
- Removed: 'Additionally, we observed favorable injection site tolerability following multiple intravenous (IV) administrations of DT-216P2.' (filed 2025-11-05)
- Removed: 'in Australia' from Phase 1 SAD clinical trial description (filed 2025-11-05)
- Removed: 'Early human PK data' replaced with 'human PK data' (filed 2026-04-28)
- Removed: 'the prior DT-216 product candidate' replaced with 'DT-216P1' in PK comparison (filed 2026-04-28)
- Removed: 'designed to evaluate' replaced with 'to evaluate' in RESTORE-FA trial description (filed 2026-04-28)
- Removed: 'and pharmacodynamics (PD)' from RESTORE-FA trial description (filed 2026-04-28)
- Removed: 'in patients with FA' from first RESTORE-FA sentence and moved later (filed 2026-04-28)
- Removed: 'following 12 weeks of dosing' from update timeline (filed 2026-04-28)
- Removed: entire paragraph 'DT-216P2 has been generally well-tolerated in these clinical trials. Based on the data from these clinical trials and non-clinical studies of DT-216P2, we believe the injection site thrombophlebitis seen with the prior DT-216 product candidate is no longer an issue limiting continued development of DT-216.' (filed 2025-11-05)
- Removed: 'The FDA's request pertains to the starting dose in the United States, which we plan to address with clinical data and, if needed, nonclinical data, in order to initiate studies for DT-216P2 in the United States.' (filed 2025-11-05)
- Reworded:
- Changed 'the prior DT-216 product candidate (DT-216P1)' to descriptive language referencing 'DT-216P1' separately as 'prior DT-216 product candidate' in newer filing (filed 2026-04-28)
- Changed 'More sustained exposure' phrasing in formulation improvement description (filed 2026-04-28)
- Changed clinical trial location reference removed from Phase 1 SAD description (filed 2026-04-28)
- Changed RESTORE-FA trial description from 'designed to evaluate' to 'to evaluate' with restructured endpoint language (filed 2026-04-28)
- Changed DT-216P2 administration routes description structure (filed 2026-04-28)
- Notes:
- The older filing text appears truncated at the end ('DT-168 ophthalmic solution in normal healthy volunteers. DT-168 eye drops were well-tolerated in all participants with a maximum dose of two 0.5% drops twice-daily for seven days. There were no serious adverse events, no ocular adverse events (AEs) and no treatment discontinuations due to AEs in the trial. All observed AEs were deemed not related to DT-168 by the trial investigator. In parallel with the Phase 1 trial, we conducted reference range studies which showed consistently different splicing in the corneal endothelium between unaffected eye donors and surgical samples from mutant TCF4 FECD patients, supporting the potential for corneal endothelium biomarkers as a clinical proof-of-concept measure of'); this comparison is limited to sections available in both filings.
Risk Factors
- Added:
- Newer filing (2026-04-28) reports an at-the-market offering of 2,006,550 shares raising $19,907 thousand in the three months ended March 31, 2026 (shown in Statements of Stockholders' Equity and Cash Flows)
- Newer filing (2026-04-28) reports 'Increase in right-of-use-asset and operating lease liability related to lease amendment' of $1,295 thousand in supplemental disclosures
- Newer filing (2026-04-28) includes 'Right-of-use asset' (no longer labeled 'related party') on balance sheet as of March 31, 2026
- Removed:
- Older filing (2025-11-05) included 'Other assets' of $427 thousand as of December 31, 2024, which is not present in newer filing
- Older filing (2025-11-05) labeled 'Right-of-use asset, related party' and 'Operating lease liability, net, related party'; newer filing (2026-04-28) removes 'related party' designations from these line items
- Older filing (2025-11-05) presented nine-month and quarterly comparative data; newer filing (2026-04-28) presents only quarterly data for three months ended March 31
- Reworded:
- Balance sheet line item changed from 'Right-of-use asset, related party' (older) to 'Right-of-use asset' (newer)
- Balance sheet line item changed from 'Operating lease liability, net, related party' (older) to 'Operating lease liability' (newer)
- Statements of Cash Flows structure changed: newer filing presents only three-month periods, older filing presented both three-month and nine-month periods
- Notes:
- The filings compare different reporting periods (Q1 2026 ended March 31, 2026 versus nine months and Q3 2025 ended September 30, 2025), which affects direct comparability of period-over-period financial metrics
- The removal of 'related party' designations from lease-related line items may reflect classification changes rather than substantive economic changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for DSGN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding DSGN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,231,463
- Reported value $45,022,772
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DSGN had 5,952,223 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DSGN had 9.51% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.96 days to cover at the same settlement.
- Reported short interest (shares) 5,952,223
- Short interest (% of shares outstanding) 9.51%
- Prior settlement (shares) 5,669,571
- Reported change 4.99%
- Days to cover (reported) 11.96
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Sarepta Therapeutics (SRPT)
- Vertex Pharmaceuticals (VRTX)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DSGN vs…
DESIGN THERAPEUTICS INC is found in…
Frequently asked questions
What does DESIGN THERAPEUTICS INC (DSGN) do?
Design Therapeutics is a clinical-stage biopharmaceutical company focused on developing a proprietary class of small-molecule medicines called GeneTAC (Gene Targeted Chimera) molecules. These molecules are designed to regulate gene expression and treat serious genetic diseases by targeting underlying genetic causes rather than just symptoms. The company's platform aims to address various genetic disorders through the modulation of gene expression.
What sector is DESIGN THERAPEUTICS INC (DSGN) in?
DESIGN THERAPEUTICS INC (DSGN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are DESIGN THERAPEUTICS INC's (DSGN) competitors?
Notable peers of DESIGN THERAPEUTICS INC (DSGN) include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Vertex Pharmaceuticals and Biogen. This peer set is informational only — not financial advice.
Is DESIGN THERAPEUTICS INC (DSGN) overbought or oversold right now?
DESIGN THERAPEUTICS INC (DSGN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DSGN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.